{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-003000","form_type":"8-K","ticker":"RLMD","cik":"0001553643","company_name":"RELMADA THERAPEUTICS, INC.","filed_at":"2024-01-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.587211+00:00","generated_at":"2026-06-07T00:32:38.456276+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Relmada Therapeutics CMO Cedric O'Gorman departs; separation agreement includes $414,500 payment","bullets":["Dr. Cedric O'Gorman's service as Chief Medical Officer ended January 3, 2024, by mutual agreement.","Separation agreement provides $414,500 payment and six months of COBRA premium coverage.","O'Gorman may exercise vested stock options under the 2021 Equity Incentive Plan until March 3, 2024, via cashless exercise.","Agreement includes confidentiality, release, and non-disparagement provisions."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-003000","json":"https://secwatch.observer/filing/0001213900-24-003000.json","markdown":"https://secwatch.observer/filing/0001213900-24-003000.md","text":"https://secwatch.observer/filing/0001213900-24-003000.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1553643/000121390024003000/0001213900-24-003000-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1553643/000121390024003000/ea191520-8k_relmada.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T00:32:38.456276+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0e61bc786d","claim":"Cedric O'Gorman departed as Chief Medical Officer at RELMADA THERAPEUTICS, INC..","evidence_excerpt":"On January 3, 2024, Dr. Cedric O’Gorman concluded his service as Chief Medical Officer of Relmada Therapeutics, Inc. (the “Company”), as mutually agreed upon between him and the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390024003000/0001213900-24-003000-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"concluded his service"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}